Lymphoma Clinical Trials in New Brunswick, New Jersey

3 studies are recruiting for lymphoma in New Brunswick, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

    Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor k…

    Stage
    Phase 1
    Ages
    Up to 25
    Site
    Local Institution - 2110, New Brunswick, New Jersey
    Locations
    68 in total
    Run by
    Turning Point Therapeutics, Inc.

    See if you can join NCT04094610 on ClinicalTrials.gov

  2. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    82 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06084936 on ClinicalTrials.gov

  3. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    40 in total
    Run by
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT07015242 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.